| 今开：61.97 | 昨收：61.75 |
| 最高：62.13 | 最低：60.81 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：1.3768838851E10 |
真灼财经06-05 11:46
$信达生物(01801)$ 目前集团已取得10款产品获批上市，3个品种的新药上市申请（NDA）在国家药品监督管理局（NMPA）审评中，5个新药分子进入III期或关键性临床研究，另外还有18个新药品种已进入临床研究。今年第一季度，集团共取得总产品收入超过17亿元（人民币，下同），按年增加60%。期内，达伯舒...查看全文
因塞特医疗(INCY)04-29 20:35
$因塞特医疗(INCY)$ DEF 14A Other definitive proxy statements Accession Number: 0001104659-24-053517 Act: 34 Size: 12 MB 网页链接查看全文
因塞特医疗(INCY)05-10 06:35
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-057330 Size: 29 KB 网页链接查看全文
因塞特医疗(INCY)05-10 06:45
$因塞特医疗(INCY)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001104659-24-059496 Act: 34 Size: 179 KB 网页链接查看全文
因塞特医疗(INCY)05-13 23:25
$因塞特医疗(INCY)$ SC TO-I Tender offer statement by Issuer Accession Number: 0001104659-24-060326 Act: 34 Size: 6 MB 网页链接查看全文
因塞特医疗(INCY)06-15 04:25
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-073677 Size: 34 KB 网页链接查看全文
因塞特医疗(INCY)05-01 04:05
$因塞特医疗(INCY)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000879169-24-000077 Act: 34 Size: 7 MB 网页链接查看全文
因塞特医疗(INCY)04-29 20:35
$因塞特医疗(INCY)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001104659-24-053519 Act: 34 Size: 871 KB 网页链接查看全文
因塞特医疗(INCY)06-11 20:25
$因塞特医疗(INCY)$ SC TO-I/A [Amend] Tender offer statement by Issuer Accession Number: 0001104659-24-070209 Act: 34 Size: 39 KB 网页链接查看全文
因塞特医疗(INCY)06-05 05:35
$因塞特医疗(INCY)$ SC TO-I/A [Amend] Tender offer statement by Issuer Accession Number: 0001104659-24-068341 Act: 34 Size: 25 KB 网页链接查看全文
张小丰2017-01-09 23:15
$因塞特(INCY)$
IDO联合PD1对实体瘤进入3期实验！ 2期数据肯定不错。等Q1的峰会看具体数据。
Additional pivotal studies evaluating Incyte’s IDO1 inhibitor in combination with Merck’s anti-PD-1 therapy in patients with non-small cell lung, renal, bladder and head and neck ...查看全文
张小丰2016-12-22 21:49
$新基制药(CELG)$ 是所有中小型Biotech的典范。严重看好新基的长期回报。
新基模式：弄出一个爆款REVLIMID（来那度胺） 然后用爆款赚的钱疯狂的研发新药，经济上自给自足。目前新基已经研发出来了2个新爆款POMALYST和OTEZLA。。而且还在积极准备下一代重量级产品CELMoDs来代替来那度胺，做好准...查看全文
scintilla2016-11-17 23:30
$因塞特(INCY)$ 和 $Tesaro(TSRO)$ 算是很靠谱的公司了，现在买了顶多回报低一些时间长点，但还是可以建起pipeline和加强肿瘤药研发能力，为以后收购打基础。 $爱力根医疗(AGN)$ 花大价钱买的那些垃圾公司很可能全部打水漂。查看全文
消费股花荣2016-11-13 21:47
$恒瑞医药(SH600276)$恒瑞的pd-1应该是遇到问题了，在几个药物公众号都看到报道因塞特医疗代理的shr-1210现在已暂停入组，需要重新对其进行全面的评估！查看全文
智通财经APP获悉，当地时间6月13日，美国FDA宣布批准礼来(LLY.US)和因塞特(INCY.US)联合开发的口服JAK抑制剂巴瑞替尼(英文商品名Olumiant)上市，用于治疗严重斑秃成人患者。值得一提的是，这是美国FDA批准用于治疗斑秃的首款系统性疗法... 网页链接
智通财经APP获悉，美国FDA于当地时间7月29日扩大了礼来(LLY.US)与因塞特医疗(INCY.US)的baricitinib药物(商用名Olumiant)的紧急适用授权(EUA)。根据修订后的EUA，治疗确诊新冠的住院患者时，baricitinib不需与吉利德科学(GILD.US)的Vekl... 网页链接
$因塞特医疗(INCY)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001104659-24-071855 Act: 34 Size: 123 KB 网页链接
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-073677 Size: 34 KB 网页链接
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000879169-24-000093 Size: 9 KB 网页链接
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000879169-24-000096 Size: 7 KB 网页链接
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000879169-24-000095 Size: 7 KB 网页链接
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000879169-24-000097 Size: 7 KB 网页链接
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000879169-24-000094 Size: 7 KB 网页链接
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000879169-24-000098 Size: 5 KB 网页链接
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000879169-24-000091 Size: 7 KB 网页链接
$因塞特医疗(INCY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000879169-24-000092 Size: 7 KB 网页链接